# Virginia National Bankshares Corp: financial statements, quarterly

VABK · Nasdaq · CIK 1572334 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vabk.md) · [Financials](/companies/vabk/financials.md) · [Filings](/companies/vabk/filings.md) · [Insiders](/companies/vabk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vabk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $k | [6,114](/filings/0000950170-23-062651.md) | [7,321 d](/filings/0000950170-24-038005.md) | [7,624](/filings/0000950170-24-060615.md) | [7,482](/filings/0000950170-24-097069.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [824](/filings/0000950170-24-124157.md) | [629 d](/filings/0000950170-25-046927.md) | [671](/filings/0000950170-25-067618.md) | [929](/filings/0000950170-25-107363.md) | [1,047](/filings/0001193125-25-277706.md) | [1,286 d](/filings/0001193125-26-128416.md) | [901](/filings/0001193125-26-219603.md) | [1,185](/filings/0001193125-26-348243.md) | [1,111](/filings/0001193125-25-277706.md) | [1,624 d](/filings/0001193125-26-128416.md) | [1,273](/filings/0001193125-26-219603.md) | [2,272](/filings/0001193125-26-348243.md) |
| Net income | $k | [4,653](/filings/0000950170-24-124157.md) | [3,168 d](/filings/0000950170-25-046927.md) | [3,646](/filings/0001193125-25-277706.md) | [4,159](/filings/0001193125-25-277706.md) | [4,600](/filings/0001193125-25-277706.md) | [4,561 d](/filings/0001193125-26-128416.md) | [4,489](/filings/0001193125-26-348243.md) | [4,238](/filings/0001193125-26-348243.md) | [4,576](/filings/0001193125-25-277706.md) | [5,958 d](/filings/0001193125-26-128416.md) | [5,259](/filings/0001193125-26-348243.md) | [9,008](/filings/0001193125-26-348243.md) |
| Diluted EPS | $ per share | [0.86](/filings/0000950170-24-124157.md) | not reported | [0.68](/filings/0000950170-25-067618.md) | [0.77](/filings/0000950170-25-107363.md) | [0.85](/filings/0001193125-25-277706.md) | not reported | [0.83](/filings/0001193125-26-219603.md) | [0.78](/filings/0001193125-26-348243.md) | [0.84](/filings/0001193125-25-277706.md) | not reported | [0.97](/filings/0001193125-26-219603.md) | [1.65](/filings/0001193125-26-348243.md) |
| Basic EPS | $ per share | [0.87](/filings/0000950170-24-124157.md) | not reported | [0.68](/filings/0000950170-25-067618.md) | [0.77](/filings/0000950170-25-107363.md) | [0.86](/filings/0001193125-25-277706.md) | not reported | [0.83](/filings/0001193125-26-219603.md) | [0.79](/filings/0001193125-26-348243.md) | [0.85](/filings/0001193125-25-277706.md) | not reported | [0.97](/filings/0001193125-26-219603.md) | [1.66](/filings/0001193125-26-348243.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [1,563](/filings/0000950170-23-062651.md) | [1,646](/filings/0000950170-25-046927.md) | [1,619](/filings/0000950170-24-060615.md) | [1,574](/filings/0000950170-24-097069.md) | [1,615](/filings/0000950170-24-124157.md) | [1,617](/filings/0001193125-26-128416.md) | [1,634](/filings/0000950170-25-067618.md) | [1,635](/filings/0000950170-25-107363.md) | [1,606](/filings/0001193125-25-277706.md) | [1,650](/filings/0001193125-26-348243.md) | [1,648](/filings/0001193125-26-219603.md) | [1,638](/filings/0001193125-26-348243.md) |
| Total liabilities | $m | [1,427](/filings/0000950170-23-062651.md) | [1,493](/filings/0000950170-25-046927.md) | [1,467](/filings/0000950170-24-060615.md) | [1,420](/filings/0000950170-24-097069.md) | [1,449](/filings/0000950170-24-124157.md) | [1,457](/filings/0001193125-26-128416.md) | [1,467](/filings/0000950170-25-067618.md) | [1,464](/filings/0000950170-25-107363.md) | [1,429](/filings/0001193125-25-277706.md) | [1,466](/filings/0001193125-26-348243.md) | [1,462](/filings/0001193125-26-219603.md) | [1,444](/filings/0001193125-26-348243.md) |
| Short-term borrowings | $m | [43.0](/filings/0000950170-23-062651.md) | [66.5](/filings/0000950170-25-046927.md) | [20.0](/filings/0000950170-24-060615.md) | [30.0](/filings/0000950170-24-097069.md) | [52.5](/filings/0000950170-24-124157.md) | [20.0](/filings/0001193125-26-128416.md) | [20.0](/filings/0000950170-25-067618.md) | [61.0](/filings/0000950170-25-107363.md) | [30.0](/filings/0001193125-25-277706.md) | [20.0](/filings/0001193125-26-348243.md) | [20.0](/filings/0001193125-26-219603.md) | [20.0](/filings/0001193125-26-348243.md) |
| Shareholders' equity | $m | [136](/filings/0000950170-24-124157.md) | [153](/filings/0001193125-26-128416.md) | [153](/filings/0001193125-25-277706.md) | [154](/filings/0001193125-25-277706.md) | [166](/filings/0001193125-25-277706.md) | [160](/filings/0001193125-26-348243.md) | [167](/filings/0001193125-26-348243.md) | [171](/filings/0001193125-26-348243.md) | [177](/filings/0001193125-25-277706.md) | [184](/filings/0001193125-26-348243.md) | [186](/filings/0001193125-26-348243.md) | [195](/filings/0001193125-26-348243.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.6 d](/filings/0000950170-24-124157.md) | [3.2 d](/filings/0000950170-25-046927.md) | [3.2](/filings/0000950170-25-067618.md) | [(6.4) d](/filings/0000950170-25-107363.md) | [15.2 d](/filings/0001193125-25-277706.md) | [3.4 d](/filings/0001193125-26-128416.md) | [2.1](/filings/0001193125-26-219603.md) | [6.7 d](/filings/0001193125-26-348243.md) | [6.0 d](/filings/0001193125-25-277706.md) | [6.5 d](/filings/0001193125-26-128416.md) | [7.2](/filings/0001193125-26-219603.md) | [3.5 d](/filings/0001193125-26-348243.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-124157.md) | [0.3 d](/filings/0000950170-25-046927.md) | [0.0](/filings/0000950170-25-067618.md) | [0.4 d](/filings/0000950170-25-107363.md) | [0.1 d](/filings/0001193125-25-277706.md) | [0.2 d](/filings/0001193125-26-128416.md) | [0.3](/filings/0001193125-26-219603.md) | [0.0 d](/filings/0001193125-26-348243.md) | [(0.1) d](/filings/0001193125-25-277706.md) | [0.4 d](/filings/0001193125-26-128416.md) | [0.2](/filings/0001193125-26-219603.md) | [0.1 d](/filings/0001193125-26-348243.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0000950170-25-067618.md) | [0.5 d](/filings/0000950170-25-107363.md) | [0.0 d](/filings/0001193125-25-277706.md) | [0.0 d](/filings/0001193125-26-128416.md) | [0.0](/filings/0000950170-25-067618.md) | [0.0 d](/filings/0000950170-25-107363.md) | [0.0 d](/filings/0001193125-25-277706.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,349](/filings/0000950170-23-062651.md) | [5,376](/filings/0000950170-24-060615.md) | [5,375](/filings/0000950170-24-097069.md) | [5,395](/filings/0000950170-24-124157.md) | [5,380](/filings/0000950170-25-067618.md) | [5,386](/filings/0000950170-25-107363.md) | [5,397](/filings/0001193125-25-277706.md) | [5,403](/filings/0001193125-26-219603.md) | [5,418](/filings/0001193125-26-348243.md) | [5,425](/filings/0001193125-25-277706.md) | [5,443](/filings/0001193125-26-219603.md) | [5,455](/filings/0001193125-26-348243.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,425,282 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-348243.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.